Pfizer debuted its Center of Excellence in Precision Medicine in Santiago, Chile, last week, bulking up in Latin America, not exactly a hot spot for pharma industry R&D.
A protein called PACS-2 plays a big role in transporting the enzyme ADAM17 into patient cells, making this an appealing target for cancer drug developers, according to a team at the University of Copenhagen.
Roche's Ventana Medical Systems has just received FDA approval of its Ventana ALK (DF53) as a companion diagnostic for Pfizer's Xalkori to treat non-small cell lung cancer.
Researchers at Johns Hopkins University found that they could predict response to Roche's cancer-fighting checkpoint inhibitor Keytruda by checking their tumors for defects in mismatch repair genes.
Women generally fare better than men after picking up cancer, but research presented at the Cancer Outcomes Conference in Belfast, Northern Ireland, found that the reverse is true among sufferers of bladder cancer. The information has informed a U.K. public advertising campaign to raise awareness of the disease.
Myriad Genetics presented data in support of its multigene myRisk heredity cancer panel and myChoice HRD companion diagnostic test at the American Society of Clinical Oncology meeting, as it scrambles to diversify revenue sources in the face of fierce competition butting heads with its flagship BRACAnalysis test for the infamous BRCA mutation.
Merck announced that it will deploy NanoString Technologies' nCounter Analysis System as it searches for more genes that predict response to its checkpoint inhibiting cancer drug Keytruda.
What if, instead of killing cancer cells, you could make them dormant? Making analogs of a highly toxic cell killer, pactamycin, investigators at Oregon State University say they have done just that. And while they're still working on a targeted delivery vehicle needed to make it safe, they add that this new approach has the potential for becoming a new class of cancer therapy that would be far "gentler" than the chemotherapies used today.
MIT and Harvard's collaborative Broad Institute just received a $10 million gift from the Gerstner Family Foundation to conduct research into drug-resistant cancers using gene-editing technology and blood-based tumor biopsies.
Adaptive Biotechnologies highlighted a study which found that its next-generation clonoSEQ genetic diagnostic has the potential to detect trace amounts of classical Hodgkin lymphoma that remains in the body following treatment.